ArticleFrontiers in oncology2023

Cost-effectiveness analysis of elacestrant versus standard endocrine therapy for second-/third-line treatment of patients with HR+/HER2- advanced or metastatic breast cancer: a US payer perspective.

Wanxian Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.